Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Ba85eee35b2d5ae1f561b89a8c6a2b465> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Ba85eee35b2d5ae1f561b89a8c6a2b465 hasDbXref "Orphanet:1923" @default.
- Ba85eee35b2d5ae1f561b89a8c6a2b465 type Axiom @default.
- Ba85eee35b2d5ae1f561b89a8c6a2b465 annotatedProperty IAO_0000115 @default.
- Ba85eee35b2d5ae1f561b89a8c6a2b465 annotatedSource MONDO_0016017 @default.
- Ba85eee35b2d5ae1f561b89a8c6a2b465 annotatedTarget "Methimazole embryopathy is a teratogenic embryofetopathy that results from maternal exposition to methimazole (MMI; or the parent compound carbimazole) in the first trimester of pregnancy. MMI is an antithyroid thionamide drug used for the treatment of Graves' disease. In the infant, MMI may result in choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomalies, congenital heart disease (such as ventricular septal defect), renal system malformations and aplasia cutis. Additional features that may be observed include facial dysmorphism (short upslanting palpebral fissures, a broad nasal bridge with a small nose and a broad forehead) and athelia/hypothelia." @default.